icon
icon
icon
icon
$300 Off
$300 Off

News /

Articles /

BiiB.US (BIIB.US) shares were down more than 5% pre-market after its Alzheimer's drug was rejected by European regulators.

Market VisionFriday, Jul 26, 2024 9:10 am ET
1min read

The European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use has rejected Leqembi, a drug developed by Japan's Eisai and Biogen to treat Alzheimer's disease, a blow to a company seeking to expand sales in one of the world's largest drug markets. The drug, which was approved in the US last year, has been slowed by logistical issues. Biogen, which has been seeking to boost its market share with the drug, which it developed in partnership with Eisai, has been hit by a decline in sales of its main multiple sclerosis drug. Biogen's shares were down 5.48 per cent in pre-trading on Friday, while BioArctic, Eisai's partner in the Nordic region for commercialising Leqembi, fell 31 per cent in Europe, the biggest single-day drop since November 2020.

Eisai's drug has already been approved in several other countries, including Japan, China and Israel. This month, Eli Lilly's Alzheimer's treatment drug Aduhelm was approved in the US, becoming the second drug to slow the disease.

Abrahams, an analyst at Royal Bank of Canada Capital Markets, estimates that Europe accounts for about 20 per cent of Leqembi's potential market. Even if an appeal overturns the decision, he said, it would delay the launch in Europe.

"It's likely to slow down global uptake of the drug and the class in general," he said.

Comments

Add a public comment...
Post
No Comment Yet
Disclaimer: The news articles available on this platform are generated in whole or in part by artificial intelligence and may not have been reviewed or fact checked by human editors. While we make reasonable efforts to ensure the quality and accuracy of the content, we make no representations or warranties, express or implied, as to the truthfulness, reliability, completeness, or timeliness of any information provided. It is your sole responsibility to independently verify any facts, statements, or claims prior to acting upon them. Ainvest Fintech Inc expressly disclaims all liability for any loss, damage, or harm arising from the use of or reliance on AI-generated content, including but not limited to direct, indirect, incidental, or consequential damages.
You Can Understand News Better with AI.
Whats the News impact on stock market?
Its impact is
fork
logo
AInvest
Aime Coplilot
Invest Smarter With AI Power.
Open App